UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4), p.845-852

2018

Volltextzugriff (PDF)

A novel role of ADGRF1 (GPR110) in promoting cellular quiescence and chemoresistance in human epidermal growth factor receptor 2‐positive breast cancer

The FASEB journal, 2021-07, Vol.35 (7), p.e21719-n/a

2021

Volltextzugriff (PDF)

Metastasis dormancy in estrogen receptor-positive breast cancer

Clinical cancer research, 2013-12, Vol.19 (23), p.6389-6397

2013

Volltextzugriff (PDF)

Adherence to oral endocrine therapy in racial/ethnic minority patients with low socioeconomic status before and during the COVID-19 pandemic

International journal of clinical pharmacy, 2023-12, Vol.45 (6), p.1396-1404

2023

Volltextzugriff (PDF)

Immunomodulator adherence in multiple myeloma patients with lower socioeconomic status: a retrospective study

Supportive care in cancer, 2024-07, Vol.32 (7), p.407, Article 407

2024

Volltextzugriff (PDF)

Dose-dependent relation between metformin and the risk of hormone receptor-positive, her2-negative breast cancer among postmenopausal women with type-2 diabetes

Breast cancer research and treatment, 2022-10, Vol.195 (3), p.421-430

2022

Volltextzugriff (PDF)

Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USA

PharmacoEconomics, 2023-06, Vol.41 (6), p.709-718

2023

Volltextzugriff (PDF)

ADGRF1 promotes tumorigenesis via the activation of STAT3 pathway in HER2+ and triple‐negative breast cancers

The FASEB journal, 2022-05, Vol.36 (S1), p.n/a

2022

Volltextzugriff (PDF)

NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer

Scientific reports, 2022-02, Vol.12 (1), p.1972-1972, Article 1972

2022

Volltextzugriff (PDF)

The changing role of ER in endocrine resistance

Breast (Edinburgh), 2015-11, Vol.24 (2), p.S60-S66

2015

Volltextzugriff (PDF)

Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications

Breast care (Basel, Switzerland), 2013-01, Vol.8 (4), p.256-262

2013

Volltextzugriff (PDF)

Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study

Breast cancer research and treatment, 2020-07, Vol.182 (2), p.401-409

2020

Volltextzugriff (PDF)

Oral Endocrine Therapy Agent, Race/Ethnicity, and Time on Therapy Predict Adherence in Breast Cancer Patients in a Large Academic Institution

Clinical breast cancer, 2020-12, Vol.20 (6), p.520-526

2020

Volltextzugriff (PDF)

High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer

Cell reports (Cambridge), 2023-08, Vol.42 (8), p.112821-112821, Article 112821

2023

Volltextzugriff (PDF)

Racial and ethnic differences in capecitabine toxicity in patients with gastrointestinal tract cancers

Annals of gastroenterology, 2022-03, Vol.35 (2), p.182-186

2022

Volltextzugriff (PDF)

Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients

The Annals of pharmacotherapy, 2019-05, Vol.53 (5), p.501-509

2019

Volltextzugriff (PDF)

Vaginal estrogen products in hormone receptor-positive breast cancer patients on aromatase inhibitor therapy

Breast Cancer Research and Treatment, 2016-06, Vol.157 (2), p.203-210

2016

Volltextzugriff (PDF)

Neratinib in HER2-Positive Breast Cancer Patients

The Annals of pharmacotherapy, 2019-06, Vol.53 (6), p.612-620

2019

Volltextzugriff (PDF)

The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis

Breast cancer research and treatment, 2015-10, Vol.153 (3), p.591-597

2015

Volltextzugriff (PDF)

Biological mechanisms and clinical implications of endocrine resistance in breast cancer

Breast (Edinburgh), 2011-10, Vol.20, p.S42-S49

2011

Volltextzugriff (PDF)

Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy

Clinical cancer research, 2015-09, Vol.21 (17), p.3995-4003

2015

Volltextzugriff (PDF)

Interventions to improve endocrine therapy adherence in breast cancer survivors: what is the evidence?

Journal of cancer survivorship, 2018-06, Vol.12 (3), p.348-356

2018

Volltextzugriff (PDF)

Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis

BMC cancer, 2019-03, Vol.19 (1), p.220-220, Article 220

2019

Volltextzugriff (PDF)

Screening of GPCR drugs for repurposing in breast cancer

Frontiers in pharmacology, 2022-12, Vol.13, p.1049640-1049640

2022

Volltextzugriff (PDF)

1 – 25 von 95

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(92)
Mit Volltextzugriff
(85)

Publikationsform

Artikel
(94)
Tagungsberichte
(1)

Sprache

Englisch
(95)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize

A novel role of ADGRF1 (GPR110) in promoting cellular quiescence and chemoresistance in human epidermal growth factor receptor 2‐positive breast cancer

Metastasis dormancy in estrogen receptor-positive breast cancer

Adherence to oral endocrine therapy in racial/ethnic minority patients with low socioeconomic status before and during the COVID-19 pandemic

Immunomodulator adherence in multiple myeloma patients with lower socioeconomic status: a retrospective study

Dose-dependent relation between metformin and the risk of hormone receptor-positive, her2-negative breast cancer among postmenopausal women with type-2 diabetes

Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USA

ADGRF1 promotes tumorigenesis via the activation of STAT3 pathway in HER2+ and triple‐negative breast cancers

NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer

The changing role of ER in endocrine resistance

Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications

Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study

Oral Endocrine Therapy Agent, Race/Ethnicity, and Time on Therapy Predict Adherence in Breast Cancer Patients in a Large Academic Institution

High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer

Racial and ethnic differences in capecitabine toxicity in patients with gastrointestinal tract cancers

Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients

Vaginal estrogen products in hormone receptor-positive breast cancer patients on aromatase inhibitor therapy

Neratinib in HER2-Positive Breast Cancer Patients

Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy

The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis

Biological mechanisms and clinical implications of endocrine resistance in breast cancer

Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy

Interventions to improve endocrine therapy adherence in breast cancer survivors: what is the evidence?

Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis

Screening of GPCR drugs for repurposing in breast cancer

Suchergebnisse filtern